Sheena Jonathan, a co-founder and director at Natera, Inc. (NASDAQ:NTRA), sold shares of the company’s common stock totaling $836,898 on July 13, 2026. The transactions involved the disposal of 3,150 shares, with prices per share ranging from $262.716 to $268.387. The sale comes as the stock trades at $277.44, just 3.7% below its 52-week high of $288.04, following an impressive 87% gain over the past year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value estimate, placing it among the most overvalued stocks tracked by the platform.
These sales were carried out pursuant to a Rule 10b5-1 trading plan, which Ms. Jonathan established on December 12, 2025.
Following these transactions, Ms. Jonathan directly holds 246,202 shares of Natera common stock. Additionally, 18,782 shares are held indirectly by the Caraluna 1 Trust and another 18,782 shares by the Caraluna 2 Trust. Ms. Jonathan disclaims beneficial ownership over the securities held by these trusts.For deeper insights into Natera’s valuation and performance metrics, InvestingPro offers a comprehensive Pro Research Report covering this and 1,400+ other US equities, transforming complex Wall Street data into actionable intelligence.
In other recent news, Natera Inc. reported significant developments concerning its Signatera test. The company announced that the test received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation, marking a key regulatory milestone. Additionally, Natera’s Signatera test gained regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency, making it the first molecular residual disease test approved in Japan for colorectal cancer. This approval sets the stage for a commercial launch by the end of 2026, pending pricing decisions.
In another development, Natera published data in JAMA Oncology showing that its MRD test can predict the benefit of chemotherapy in liver cancer patients. The study was conducted with 298 patients and presented at the European Society for Medical Oncology Gastrointestinal Congress. Furthermore, Natera has partnered with Aveta Biomics for a Phase 3 clinical trial to evaluate a treatment for head and neck cancer, utilizing the Signatera test to monitor disease and treatment response.
Lastly, Bernstein SocGen Group resumed coverage of Natera with an outperform rating, highlighting the company’s potential for increased volumes and reimbursement in minimal residual disease testing. The firm pointed to Japan as a key market driver with anticipated commercial activities by the year’s end.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
